Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Enhertu Now under US Review for Post-Neoadjuvant HER2 Breast Cancer
Daiichi Sankyo said on March 9 that the US FDA has accepted for review a supplemental biologics license application for its anti-HER2 antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) seeking a new indication in HER2-positive early breast cancer. The company…
To read the full story
Related Article
- Enhertu Earns 2 US Approvals in HER2-Positive Early Breast Cancer
May 19, 2026
- Enhertu Filed in Japan as Adjuvant Therapy for Early Breast Cancer
March 2, 2026
- Enhertu Accepted for EU Review in Post-Neoadjuvant HER2 Breast Cancer
February 20, 2026
- Enhertu Wins US Breakthrough Tag in Post-Neoadjuvant HER2 Breast Cancer
December 23, 2025
BUSINESS
- Keytruda Keeps Top Spot in Japan in April-June as Mounjaro Zooms: IQVIA
August 19, 2026
- LEO Pharma Buys Global Rights to Tanabe’s EPP/XLP Drug
August 19, 2026
- J-TEC to Explore Regenerative Medicine Licensing Opportunities in Taiwan
August 19, 2026
- Shionogi to Effectively Scrap Mandatory Retirement from FY2027
August 19, 2026
- Chugai Out-Licenses Anti-Dengue Antibody AID351 to GSK
August 19, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…